Background: Intracranial arterial stenosis is a rare cause of stroke in Caucasians. Detection of clinically silent circulating microemboli by transcranial Doppler sonography is now widely investigated in patients with carotid artery disease in the hope to identify patients at increased risk for stroke. Methods: In 33 patients with intracranial internal carotid (n = 12), middle cerebral (n = 18), posterior cerebral (n = 2), or basilar artery stenosis (n = 1), we performed a 1-hour microembolus detection downstream to the stenosis in the middle or in the posterior cerebral artery, respectively. The stenosis was assessed by transcranial Doppler and duplex ultrasound. 18 patients had been symptomatic in the dependent territory. Results: Five patients with ischaemic symptoms within the last 8 days and with a peak systolic flow velocity of ≧210 cm/s in the stenosis showed microembolic signals at a rate of 3–25 events/h, despite effective anticoagulation. All these 5 patients had a lesion pattern on cranial CT or MRI scan suggesting embolic origin. All the asymptomatic patients (n = 15) and all the patients with a peak systolic intrastenostic velocity of 160 to <210 cm/s (n = 13) did not show microembolic signals at all. Conclusion: Microembolic signals occur in recently symptomatic patients with high-grade intracranial arterial stenosis indicated by a sonographically measured stenotic peak flow velocity of ≧210 cm/s. Therapeutic anticoagulation was not sufficient to suppress microemboli formation.

1.
Sacco RL, Kargman DE, Gu Q, Zamanillo MC: Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995;26:14–20.
2.
Lyrer PA, Engelter S, Radu EW, Steck AJ: Cerebral infarcts related to isolated middle cerebral artery stenosis. Stroke 1997;28:1022–1027.
3.
Spencer MP, Thomas GI, Nicholls SC, Sauvage LR: Detection of middle cerebral artery emboli during carotid endarterectomy using transcranial Doppler ultrasonography. Stroke 1990;21:415–423.
4.
Spencer MP: Detection of cerebral arterial emboli; in Newell DW, Aaslid R (eds): Transcranial Doppler. New York, Raven Press, 1992, pp 216–230.
5.
Nabavi DG, Georgiadis D, Mumme T, Zunker P, Ringelstein EB: Detection of microembolic signals in patients with middle cerebral artery stenosis by means of a bigate probe. A pilot study. Stroke 1996;27:1347–1349.
6.
Sliwka U, Klötzsch C, Popescu O, Brandt K, Schmidt P, Berlit P, Noth J, Klotzsch C: Do chronic middle cerebral artery stenoses represent an embolic focus? A multirange transcranial Doppler study. Stroke 1997;28:1324–1327.
7.
Segura T, Serena J, Molins A, Davalos A: Clusters of microembolic signals: A new form of cerebral microembolism presentation in a patient with middle cerebral artery stenosis. Stroke 1998;29:722–724.
8.
Droste DW, Markus HS, Brown MM: The effect of different settings of ultrasound pulse amplitude, gain and sample volume on the appearance of emboli studied in a transcranial Doppler model. Cerebrovasc Dis 1994;4:152–156.
9.
Droste DW, Ringelstein EB: Detection of high intensity transient signals (HITS): How and why? Eur J Ultrasound 1998;7:23–29.
10.
Consensus Committee of the 9th International Cerebral Hemodynamics Symposium: Basic identification criteria of Doppler microembolic signals. Stroke 1995;26:1123
11.
Ringelstein EB, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, Markus HS, Russell D, Siebler M: Consensus on microembolus detection by transcranial Doppler ultrasound. Stroke 1998;29:725–729.
12.
Droste DW, Schlossberg R, Mitusch R, Kaps M: Low frequency of clinically silent circulating emboli in patients with mitral valve prolapse or patent foramen ovale detected by transcranial Doppler ultrasound. Neurol Res 1998;20:499–503.
13.
Ringelstein EB, Koschorke S, Holling A, Thron A, Lambertz H, Minale C: Computed tomographic patterns of proven embolic brain infarctions. Ann Neurol 1989;26:759–765.
14.
Siebler M, Kleinschmidt A, Sitzer M, Steinmetz H, Freund H-J: Cerebral microembolism in symptomatic and asymptomatic high-grade internal carotid artery stenosis. Neurology 1994;44:615–618.
15.
Droste DW, Dittrich R, Kemény V, Schulte-Altedorneburg G, Ringelstein EB: Prevalence and frequency of microembolic signals in 105 patients with extracranial carotid artery occlusive disease. J Neurol Neurosurg Psychiat 1999;67:525–528.
16.
Markus HS, Thomson ND, Brown MM: Asymptomatic cerebral embolic signals in symptomatic and asymptomatic carotid artery disease. Brain 1995;118:1005–1011.
17.
Siebler M, Sitzer M, Rose G, Bendfeldt D, Steinmetz H: Silent cerebral embolism caused by neurologically symptomatic high-grade carotid stenosis. Brain 1993;116:1005–1015.
18.
Bornstein NM, Norris JW: The unstable carotid plaque. Stroke 1989;20:1104–1106.
19.
Fisher M, Blumenfeld AM, Smith TW: The importance of plaque disruption and hemorrhage. Arch Neurol 1987;44:1086–1089.
20.
Sillesen H, Nielsen T: Clinical significance of intraplaque hemorrhage in carotid artery disease. J Neuroimaging 1998;8:15–19.
21.
Grosset DG, Georgiadis D, Abdullah I, Bone I, Lees KR: Doppler emboli signals vary according to stroke subtype. Stroke 1994;25:382–384.
22.
Benesch CG, Chimowitz MI, for the WASID Investigators: Best treatment for intracranial arterial stenosis? 50 years of uncertainty. Neurology 2000;55:465–466.
23.
Mitka M: Results of CURE trial for acute coronary syndrome. JAMA 2001;285:1828–1829.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.